格列本脲治疗动脉瘤性蛛网膜下腔出血:一项随机对照临床试验
这项随机对照试验纳入78例动脉瘤性蛛网膜下腔出血患者,随机分配接受口服格列本脲5 mg(38例)或安慰剂(40例)治疗21天。格列本脲未改善6个月功能结局(mRS序贯分析未调整共同OR 0.66,95%CI 0.29-1.48;调整后共同OR 1.25,95%CI 0.46-3.37),死亡率及迟发性脑缺血亦无差异,低血糖在格列本脲组更常见(5.3%)。
要点
- 格列本脲未改善动脉瘤性蛛网膜下腔出血患者6个月功能结局(mRS)。
- 格列本脲组与安慰剂组死亡率和迟发性脑缺血发生率相似。
- 低血糖在格列本脲组更常见(5.3%)。
核心结论
- 在本研究中,格列本脲与动脉瘤性蛛网膜下腔出血后更好的功能结局无关,死亡率和迟发性脑缺血发生率与安慰剂相比也相似。
研究设计与样本
- 随机对照临床试验,纳入放射学确诊的动脉瘤性蛛网膜下腔出血患者,年龄18至70岁,发病96小时内就诊,随机分配接受口服格列本脲5 mg或安慰剂治疗21天,采用改良意向性治疗分析,共78例(格列本脲组38例,安慰剂组40例)。
主要发现
- 格列本脲未改善6个月功能结局(mRS序贯分析,未调整共同OR 0.66[95%CI 0.29-1.48],调整后共同OR 1.25[95%CI 0.46-3.37])。
- 6个月mRS二分类分析(有利评分0-2)、出院时mRS评分(序贯或二分类)、死亡率及迟发性脑缺血等次要结局均得到相似结果。
- 低血糖在格列本脲组更常见(5.3%)。
- 患者平均年龄53.1岁,大多数为女性(75.6%);Hunt和Hess评分、世界神经外科医师联盟(WFNS)评分及改良Fisher量表(mFS)评分中位数分别为3(IQR 2-4)、3(IQR 3-4)、3(IQR 1-4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glibenclamide has been shown to improve outcomes in cerebral ischemia, traumatic brain injury, and subarachnoid hemorrhage (SAH). The authors sought to evaluate glibenclamide's impact on mortality and functional outcomes of patients with aneurysmal SAH (aSAH). METHODS: Patients with radiologically confirmed aSAH, aged 18 to 70 years, who presented to the hospital within 96 hours of ictus were randomly allocated to receive 5 mg of oral glibenclamide for 21 days or placebo, in a modified intention-to-treat analysis. Outcomes were mortality and functional status at discharge and 6 months, evaluated using the modified Rankin Scale (mRS). RESULTS: A total of 78 patients were randomized and allocated to glibenclamide (n = 38) or placebo (n = 40). Baseline characteristics were similar between groups. The mean patient age was 53.1 years, and the majority of patients were female (75.6%). The median Hunt and Hess, World Federation of Neurosurgical Societies (WFNS), and modified Fisher scale (mFS) scores were 3 (IQR 2-4), 3 (IQR 3-4), and 3 (IQR 1-4), respectively. Glibenclamide did not improve the functional outcome (mRS) after 6 months (ordinal analysis, unadjusted common OR 0.66 [95% CI 0.29-1.48], adjusted common OR 1.25 [95% CI 0.46-3.37]). Similar results were found for analyses considering the dichotomized 6-month mRS score (favorable score 0-2), as well as for the secondary outcomes of discharge mRS score (either ordinal or dichotomized), mortality, and delayed cerebral ischemia. Hypoglycemia was more frequently observed in the glibenclamide group (5.3%). CONCLUSIONS: In this study, glibenclamide was not associated with better functional outcomes after aSAH. Mortality and delayed cerebral ischemia rates were also similar compared with placebo.
引用
- Costa BBSD, Windlin IC, Koterba E, et al. Glibenclamide in aneurysmal subarachnoid hemorrhage: a randomized controlled clinical trial. J Neurosurg. 2021. PMID: 34798604. doi:10.3171/2021.7.JNS21846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。